IDEAYA Biosciences News

IDEAYA Biosciences to Participate in Upcoming May 2024 Investor Relations Event

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...

PR NewswireMay 1 06:00 ET

Express News | IDEAYA Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

ReutersApr 26 06:00 ET

IDEAYA Biosciences Announces ASCO 2024 Oral Presentation For Darovasertib In Neoadjuvant Uveal Melanoma Phase 2 Investigator Sponsored Study

Oral presentation at ASCO 2024 scheduled for Monday, June 3, 2024, at 9:51 AM CDTThe abstract summary will be available on Thursday, May 23, 2024 at ~5:00pm ETSOUTH SAN FRANCISCO, Calif., April 24, 20

BenzingaApr 24 10:06 ET

Express News | IDEAYA Biosciences Announces Selection of Move-Forward Phase 2 Expansion Dose for Ide397 Monotherapy in Mtap-Deletion Squamous Non-Small Cell Lung Cancer

Moomoo 24/7Apr 22 06:00 ET

IDEAYA Biosciences Announces Selection of Move-Forward Phase 2 Expansion Dose for IDE397 Monotherapy in MTAP-Deletion Squamous Non-Small Cell Lung Cancer

Selected a move-forward Phase 2 expansion dose for IDE397 monotherapy in MTAP-deletion squamous NSCLC, based on AE profile and preliminary clinical efficacy observed, including multiple partial responses by RECIST 1.1

PRNewswireApr 22 06:00 ET

IDEAYA Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...

PR NewswireApr 5 06:00 ET

IDEAYA Biosciences to Participate in Upcoming April 2024 Investor Relations Event

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...

PR NewswireApr 1 06:00 ET

IDEAYA Biosciences Is Maintained at Buy by Citigroup

IDEAYA Biosciences Is Maintained at Buy by Citigroup

Dow JonesMar 21 12:26 ET

Express News | Citigroup Maintains Buy on IDEAYA Biosciences, Raises Price Target to $60

Moomoo 24/7Mar 21 12:17 ET

Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL), IDEAYA Biosciences (IDYA) and Vor Biopharma (VOR)

TipRanksMar 21 06:20 ET

Strong Buy Rating for IDEAYA Biosciences Based on Strategic Partnership and Promising Oncology Pipeline

TipRanksMar 13 11:15 ET

Express News | Ideaya Biosciences Has Entered Into A Clinical Trial Collaboration And Supply Agreement With Merck To Evaluate Its IDEE161 In Combination With Keytruda (Pembrolizumab) For Endometrial Cancer, In A Phase 1 Trial

Moomoo 24/7Mar 12 06:11 ET

Big Pharma Patent Cliffs Seen Fueling Oncology M&A This Year

Seeking AlphaMar 10 13:08 ET

Demystifying IDEAYA Biosciences: Insights From 6 Analyst Reviews

In the last three months, 6 analysts have published ratings on IDEAYA Biosciences (NASDAQ:IDYA), offering a diverse range of perspectives from bullish to bearish.The following table provides a quick o

BenzingaMar 8 15:00 ET

IDEAYA a New Buy at BTIG on Underappreciated Pipeline

Seeking AlphaMar 8 12:11 ET

Express News | BTIG Initiates Coverage On IDEAYA Biosciences With Buy Rating, Announces Price Target of $55

Moomoo 24/7Mar 8 09:15 ET

IDEAYA Biosciences to Participate in Upcoming March 2024 Investor Relations Events

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...

PR NewswireMar 4 06:00 ET

Analysts Are Bullish on These Healthcare Stocks: IDEAYA Biosciences (IDYA), Insulet (PODD)

TipRanksFeb 25 23:40 ET

IDEAYA Biosciences Price Target Raised to $57.00/Share From $51.00 by JP Morgan

IDEAYA Biosciences Price Target Raised to $57.00/Share From $51.00 by JP Morgan

Dow JonesFeb 23 12:32 ET

IDEAYA Biosciences Is Maintained at Overweight by JP Morgan

IDEAYA Biosciences Is Maintained at Overweight by JP Morgan

Dow JonesFeb 23 12:32 ET